Wang Wen-Ming, Jin Hong-Zhong
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
J Dermatol. 2023 Apr;50(4):415-421. doi: 10.1111/1346-8138.16702. Epub 2023 Jan 18.
Psoriasis is a chronic inflammatory skin disorder with a chronic relapsing course. Biologics have revolutionized the treatment of adult psoriasis with higher efficacy and favorable safety profile. Recently, more studies have focused on the use of biologics in pediatric psoriasis, and several biologics have been approved for use therein. This review is divided into two sections: the first part focuses on real-world studies on the use of biologics in pediatric psoriasis and the second part summarizes the findings of other clinical trials related to biologics in pediatric psoriasis. Case reports have been excluded from this review. Several biologics were used for treating pediatric psoriasis and the efficacy is encouraging. According to the studies included in this review, anti-IL-12/23 and anti-IL-17A for treating pediatric psoriasis might have a better efficacy than anti-TNF-α, but more data are needed.
银屑病是一种具有慢性复发性病程的慢性炎症性皮肤病。生物制剂以更高的疗效和良好的安全性彻底改变了成人银屑病的治疗。最近，更多研究聚焦于生物制剂在儿童银屑病中的应用，并且几种生物制剂已获批用于该领域。本综述分为两个部分：第一部分重点关注生物制剂在儿童银屑病中应用的真实世界研究，第二部分总结其他与儿童银屑病生物制剂相关的临床试验结果。本综述已排除病例报告。几种生物制剂用于治疗儿童银屑病，其疗效令人鼓舞。根据本综述纳入的研究，用于治疗儿童银屑病的抗IL - 12/23和抗IL - 17A可能比抗TNF -α具有更好的疗效，但还需要更多数据。
